All articles
Clay illustration of a health center worker feeding claim cards into a 340B ESP machine, with locked claims moving on a conveyor toward a drug manufacturer

340B ESP Explained: What Covered Entities Must Submit in 2026

What 340B ESP is, which manufacturers now require claims data for in-house dispenses, the deadlines, and how the 2027 rebate pilot uses Beacon.

Remy Healthcare Team

Remy Healthcare Team

17 min read · November 21, 2026

In this article

A manufacturer letter lands in a health center pharmacy director's inbox. Starting next month, it says, the center must upload claims data for every 340B dispense, including prescriptions filled at its own in-house pharmacy, or lose 340B pricing on that company's drugs. The letter names one website: 340B ESP.

Eli Lilly, Novo Nordisk, AstraZeneca, Bristol Myers Squibb, Amgen and Genentech each sent a version of that letter in 2026 (Cencora, 340B Manufacturer Updates). In the same year HRSA approved a rebate pilot that starts January 1, 2027 and runs on a sister platform called Beacon. This guide explains what 340B ESP is, what it collects, which rules changed, and what a covered entity should have in place before the pilot begins. It reflects manufacturer notices and HRSA actions published through November 2026.

What is 340B ESP?

340B ESP is a web platform where covered entities register, designate contract pharmacies and upload the 340B claims data that drug manufacturers require as a condition of 340B pricing. Second Sight Solutions runs it, and Rx Almanac's vendor profile lists Second Sight as a subsidiary of Berkeley Research Group (Rx Almanac, Second Sight Solutions vendor profile, October 2026). That ownership is why Cencora's manufacturer tracker refers to it as BRG's platform.

The platform's help center says it supports both contract pharmacy and in-house manufacturer policies (340B ESP Help Center, Frequently Asked Questions). Its reach is wide. In comments summarized in HRSA's August 2026 Federal Register notice, a technology vendor reported that more than 7,000 covered entities had already submitted data through 340B ESP (HRSA, Notice Regarding 340B Rebate Model Pilot Program, 91 FR 48883, August 3, 2026).

340B ESP is not an HRSA system. Its own help center notes that HRSA has not commented publicly on the platform. The obligation to use it comes from each manufacturer's policy and covers only that manufacturer's drugs. One covered entity can therefore face a different deadline, data scope and state exemption for every company it buys from.

Why do manufacturers require claims data?

Manufacturers say they need claims data to catch duplicate discounts. Many covered entities see the requirements as a way to limit contract pharmacy use. Both readings appear in the public record.

HRSA's own account is direct. In a footnote to its 2026 rebate notice, the agency wrote that "in 2021, several participating 340B manufacturers sought to limit the number and kinds of contract pharmacies to which they would ship orders by requiring certain claims level data." HRSA first told those manufacturers they had to deliver to any contract pharmacy a covered entity chose. The D.C. Circuit later held, in Novartis Pharmaceuticals Corp. v. Johnson (2024), that manufacturers had discretion to impose certain conditions on delivery (HRSA, 91 FR 48883).

The stated purpose also reaches past the 340B statute. The statute's duplicate discount rule concerns Medicaid rebates, and HRSA's notice cites section 340B(a)(5)(A) of the Public Health Service Act for it. The 340B ESP help center says uploaded data may be used to identify duplicate Medicaid, Medicare, TRICARE and commercial payer rebates. When Second Sight updated its terms of use in October 2021, the advocacy group RWC-340B flagged that change, along with a clause saying continued use of the platform counts as acceptance of later versions (RWC-340B, Second Sight Updates 340B ESP Terms of Use).

For a health center, that means the terms you accept on 340B ESP are a vendor agreement, and they can change after you sign up.

Which manufacturers changed their 340B ESP rules in 2026?

The 2026 change was scope. The first conditions, in 2021, were tied to contract pharmacy use. The 2026 notices extend them to in-house pharmacy dispenses and, for several manufacturers, to medical claims for drugs administered in the clinic.

ManufacturerEffectiveWhat the 2026 notice requires
Eli LillyFeb 1, 2026Claims data for all 340B dispenses, including in-house pharmacy
Novo NordiskApr 1, 2026Pharmacy and medical claims for all 340B dispenses, including in-house, through 340B ESP within 45 days of dispense
AstraZenecaMay 1, 2026Claims for all 340B utilization of specified products, through 340B ESP
Bristol Myers SquibbMay 1, 2026Claims-level data from all covered entities
OrganonMay 1, 2026Pharmacy claims move from 340B ESP to Truzo
AmgenJun 1, 2026Pharmacy and medical claims for all 340B dispenses, in-house and contract pharmacy
BiogenJun 1, 2026Claims data for Avonex, Plegridy, Tecfidera and Vumerity from all covered entity types
GSKJul 1, 2026In-house claims data as a condition of 340B pricing
GileadJul 7, 2026Contract pharmacy program moves from 340B ESP to Truzo by Kalderos
GenentechAug 31, 2026Pharmacy and medical claims from all covered entity types

Sources: Cencora's manufacturer updates tracker, Novo Nordisk's 340B notice and RxTrail for Organon. Manufacturers revise these notices often, so confirm the current version before acting on any row.

Two details in this list matter more than the dates. First, Cencora records that Amgen would begin seeking standard healthcare visit and service claims data on November 15, 2026. That is information about the visit itself, beyond the prescription. Second, the windows differ. RxTrail reports that Lilly allows 45 days for most products and 60 days for a specific set of drugs, and Cencora records that Bristol Myers Squibb lengthened its window to 45 days from 14 (RxTrail, Spring 2026 340B Manufacturer Policy Updates, April 17, 2026).

The rules are also being tested in court. HFMA reports that Tampa General Hospital and Mary Hitchcock Memorial Hospital filed federal lawsuits in July 2026 challenging Lilly's claims data policy, and that hospital groups filed an amicus brief supporting them in October (HFMA, 340B rebate model takes shape for 2027, October 2026).

What data does 340B ESP collect?

For pharmacy claims, the fields in the 340B ESP help center include the 340B ID, date of service, date prescribed, NDC, prescriber ID, quantity, Rx number, fill number, dispensing pharmacy ID and wholesaler invoice number, plus payer BIN and PCN where the manufacturer requires them. Medical claims use the claim number and line number, date of service, HCPCS code and modifier, NDC-11, rendering physician ID, quantity, unit of measure, service provider ID, and health plan name and ID. The help center also describes Data + Encounter formats that add fields such as ICD-10 diagnosis codes.

The Rx number and product serialization number are hashed before they leave your computer. According to the help center, the platform applies SHA-3 hashing with an added salt inside your browser, the process received a HIPAA Expert Determination, and Second Sight offers covered entities a standard business associate agreement (340B ESP Help Center).

Hashing hides the prescription number. It does not hide the date, drug, quantity, prescriber or payer, and those are the fields a manufacturer uses to match a claim against rebate records. Your compliance team should review the upload the way it reviews any other disclosure of claims detail, and your 340B policies should name who approves it.

How do you register and submit claims?

Register the covered entity once, designate contract pharmacies, then upload on a fixed schedule. The steps below come from the 340B ESP help center unless noted.

Create one account per covered entity. Registration at 340besp.com/register asks for your contact information, your covered entity and an authorization, along with agreement to the terms of use and privacy policy. ESP then verifies a unique phone number for two-factor authentication and an organization email address, and emails an invitation to create credentials. A covered entity can be registered to only one account, and the first registered user becomes its administrator, so choose that person on purpose.

Register even if you serve only uninsured patients. The help center says those entities should still register and may complete an attestation form.

Designate contract pharmacies. Designations are made on the 340B ESP designations page or in the entity profile. Only pharmacies that HRSA lists as active can be designated.

Upload on a calendar. Claims can be submitted as soon as they qualify as 340B eligible. Novo Nordisk asks for data within 45 days of dispense and encourages uploads on the 1st and 16th of each month (Novo Nordisk, Hospital and Grantee 340B Distribution Policy notice). A twice monthly cycle fits inside every window in the table above and leaves time to fix rejected claims.

Ask whether your TPA can submit for you. Your third party administrator (TPA) already holds most of the data. In the HRSA notice, a rebate platform vendor said 53 TPAs could submit directly to its platform as of spring 2026. If yours can, get in writing which manufacturers it covers, how often it uploads, and how it reports rejected claims back to you. If you are evaluating a 340B TPA, put those three questions in the RFP.

What happens if you miss a deadline?

Each manufacturer sets its own consequence, and the usual one is losing 340B pricing on its drugs until the data is submitted. Novo Nordisk's notice is one of the few that spells it out. Missing in-house claims data may suspend access to 340B pricing until the data arrives. For an entity that relies on one designated contract pharmacy, a missed submission may suspend 340B-priced shipments to that pharmacy.

The same notice describes a single designated contract pharmacy for grantees and hospitals that do not have an in-house pharmacy, and that pharmacy cannot be a central fill pharmacy. Read the whole notice, because its designation and data rules interact. Cencora records a similar single designated pharmacy rule from Amphastar, effective July 1, 2026.

In practice, a missed upload means buying that manufacturer's drugs at non-340B prices until the data catches up. That cost comes out of the same savings a health center uses to fund patient services.

How is 340B ESP different from Beacon and Truzo?

340B ESP supports upfront 340B pricing with data conditions attached. Beacon processes rebates. Truzo is a competing claims platform run by Kalderos.

Beacon Channel Management is a rebate platform. ACI 340B Management and Rx Almanac both describe it as a Second Sight Solutions product, from the same company behind 340B ESP (ACI 340B Management, HRSA Approves 340B Rebate Models for Nine Drugs, November 2025). Under a rebate model the covered entity buys the drug at wholesale acquisition cost, submits the claim, and the manufacturer pays back the difference between that price and the 340B ceiling price. HFMA reports that all ten manufacturers approved for HRSA's 2027 pilot use Beacon for pharmacy and medical claims (HFMA).

Truzo by Kalderos is a separate platform. Gilead moved its contract pharmacy program to Truzo effective July 7, 2026, according to Cencora, and RxTrail reports that Organon moved its pharmacy claims there effective May 1, 2026.

A health center that buys from a broad set of manufacturers can need accounts on all three platforms in 2027, each with its own upload format, schedule and rejection queue. For the cash flow side of rebates, see our explainer on how a 340B rebate model works.

What does the 2027 rebate pilot change?

Starting January 1, 2027, ten manufacturers will deliver the 340B price on 21 drugs as a rebate paid through Beacon instead of an upfront discount. HRSA announced the approved manufacturers and drugs on October 1, 2026 (HFMA). The drugs are ones selected for Medicare drug price negotiation, and HRSA's notice puts the products in scope at less than 5.5 percent of total 340B sales, based on 2025 data.

Getting here took two attempts. HRSA approved a first set of rebate plans in October 2025 for a January 2026 start (Feldesman, January 2, 2026). The American Hospital Association and others sued in the District of Maine, which granted a preliminary injunction on December 29, 2025 (NACHC, 340B Rebate Model Pilot Program). HRSA paused the pilot, the First Circuit declined to stay the injunction (340B Health, January 8, 2026), and the pilot was withdrawn in February 2026 (Frier Levitt, September 1, 2026). On July 21, 2026, the D.C. Circuit affirmed in Novartis Pharmaceuticals Corp. v. Kennedy that manufacturers may not implement rebate models without HHS approval, as HRSA's notice records. HRSA published the revised pilot less than two weeks later.

The revised notice sets rules that every approved plan must follow (HRSA, 91 FR 48883):

A 45 day window. Covered entities must be allowed to submit data up to 45 calendar days from the date of dispense, with allowances for exceptions such as a 340B status change on a claim.

A 10 day payment clock. Rebates must be paid, or denied with documentation, within 10 calendar days of a completed submission. If a submission is returned as incomplete, the clock restarts once the missing data arrives.

No denials over diversion or duplicate discount suspicions. A manufacturer with those concerns must raise them with HRSA or use audits and administrative dispute resolution instead of withholding the rebate.

A fixed list of data fields. Plans are limited to the pharmacy and medical fields HRSA lists, which closely track the 340B ESP formats above. HRSA says purchasing data and encounter data should not be requested, and claims for uninsured or cash paying patients can be marked "CASH."

Limits on reuse. Pilot data should not be used for any other purpose, a limit HRSA says extends to collecting, aggregating, sharing or licensing it.

A quarterly price file. Manufacturers must publish a 340B price file for each 11-digit NDC so entities can bill Medicaid at actual acquisition cost and set sliding fee charges.

Set those rules beside the 340B ESP terms. Inside the pilot, encounter data is excluded and reuse is restricted. Outside it, each manufacturer's policy sets its own terms, and at least one has started asking for visit-level data. Most health centers will work under both sets of rules at once in 2027.

The pilot list also hits primary care directly. NACHC's list includes Eliquis, Jardiance, Farxiga and Januvia, so a health center will pay wholesale acquisition cost for those drugs at purchase and wait for the rebate. HFMA reports that the American Hospital Association is considering all available options to stop the revised pilot, so watch for new litigation before January.

What should an FQHC do now?

Build a manufacturer matrix. Make one row for each manufacturer whose drugs you buy at 340B prices. Record which channels need data (contract pharmacy, in-house, medical), which platform (340B ESP, Beacon, Truzo), the submission window, any state waiver, and the date you last checked the notice. Cencora's tracker is a practical place to start.

Check your state. Several manufacturers carve out states, usually ones that have passed contract pharmacy protection laws, and the carve outs are not uniform. Novo Nordisk's notice lists the states where it waives the data condition and names FQHCs and look-alikes in New Mexico specifically. AstraZeneca exempts Louisiana only for entities that register and submit claims through Second Sight, per Cencora.

Assign the upload in writing. Name the person or vendor responsible for each manufacturer and each channel in your 340B policies and procedures. Auditors review how the program actually runs, and our 340B audit checklist for FQHCs covers what they ask for.

Reconcile rejections twice a month. Match your review to the upload cycle so a rejected batch gets fixed inside the window instead of after it.

Set up Beacon before January 1, 2027. Confirm whether your TPA will submit pilot claims for you, check which of the 21 pilot drugs you dispense, and plan the cash to buy them at wholesale acquisition cost. HRSA's notice includes a grace period for up to two unreplenished accumulated packages dispensed in the 15 days before the start date, and those rebate requests still have to be made within 45 days of dispense.

Keep a record of what you agreed to. Save each version of the 340B ESP terms of use and the date each user accepted it. RWC-340B notes that Second Sight is not required to notify covered entities when the terms change.

If your pharmacy setup is part of the decision, our guide to in-house, contract and hybrid pharmacy models compares the three. For ongoing help running the program, see 340B program management.

Which of your manufacturers would cut off 340B pricing first if this month's upload never went out?

Frequently Asked Questions

What is the 340B ESP login?
Covered entities sign in at 340besp.com. New users register at 340besp.com/register, verify a phone number for two-factor authentication and an organization email address, and then receive an email invitation to create credentials. Each covered entity can hold only one account, and the first registered user becomes its administrator.
Does HRSA require covered entities to use 340B ESP?
No. 340B ESP is a condition set by individual manufacturers, and the platform's own help center says HRSA has not commented publicly on it. HRSA's August 2026 notice explains that the agency initially disallowed claims data conditions in 2021, and that the D.C. Circuit later held in Novartis v. Johnson (2024) that manufacturers had discretion to impose certain conditions on delivery.
Is 340B ESP free for covered entities?
Rx Almanac's vendor profile describes 340B ESP as a manufacturer-funded platform with free submission for covered entities. The real cost is staff time or TPA fees for mapping claims, uploading them on schedule and fixing rejections.
How often should we upload claims to 340B ESP?
Twice a month is a sensible minimum. Novo Nordisk encourages uploads on the 1st and 16th of each month and requires data within 45 days of dispense, and other manufacturers use similar 45 day windows, with some drugs on longer ones. The platform accepts claims as soon as they qualify as 340B eligible.
What is the difference between 340B ESP and Beacon?
340B ESP collects the claims data manufacturers require before they honor upfront 340B pricing, at contract pharmacies and, since 2026, often in-house as well. Beacon processes rebate claims, where the covered entity pays wholesale acquisition cost first and the manufacturer pays the 340B difference back. Both are Second Sight Solutions products, and all ten manufacturers in HRSA's 2027 rebate pilot use Beacon.
Do we need to register if we only serve uninsured patients?
Yes. The 340B ESP help center says covered entities that serve only uninsured patients should still register, and that they may complete an attestation form.

Sources

Get a second look at your 340B data flows

Remy's 340B team reviews contract pharmacy, in-house and claims data workflows for covered entities and shows you where the gaps are before a manufacturer or an auditor finds them.

Talk to a 340B specialist
340BComplianceFQHCsDrug Pricing
Remy Healthcare Team

Written by

Remy Healthcare Team

340B & FQHC Specialists

The Remy team advises FQHCs and 340B covered entities on program management, infusion operations, and revenue optimization.